Abstract
Acute Lymphoblastic Leukemia (ALL) is the most common childhood cancer, presenting significant challenges in early diagnosis and effective treatment. Recent advances in gene profiling have identified a pivotal role for the TEL-AML1 (ETV6-RUNX1) gene fusion, present in about one quarter of pediatric ALL cases. This gene fusion is often associated with a more benign course and requires additional genetic abnormalities known as Second Hits, to cause overt leukemia. Our current study utilizes Fuzzy Cognitive Maps (FCMs) to model the intricate genetic interplays and potential progression paths of ALL in children, focusing on those with the TEL-AML1 gene fusion within a familial leukemia context.
In this virtual longitudinal study, we leverage cohorts of aiHumanoid simulations to explore the foundational role of the TEL-AML1 fusion gene in the genesis of ALL, examining its impact when combined with a family history of leukemia. The simulations predict how genetic and environmental factors might influence disease onset and progression, providing a platform for early diagnosis and progression monitoring.
Our findings suggest that family history significantly increases the risk and modifies the disease course in carriers of the TEL-AML1 fusion gene, indicating a need for targeted surveillance and potential early interventions in these high-risk groups.
Competing Interest Statement
The author is an unpaid founder of 123Genetix Inc.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The virtual subject data was created by GPT4 based on population epidemiological data as of December 2023. No actual subject data was used in this study
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data is contained in the paper
